|
1
|
Giordano S and Columbano A: MicroRNAs: New
tools for diagnosis, prognosis, and therapy in hepatocellular
carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Poon D, Anderson BO, Chen LT, Tanaka K,
Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al Asian
Oncology Summit: Management of hepatocellular carcinoma in Asia:
Consensus statement from the Asian Oncology Summit 2009. Lancet
Oncol. 10:1111–1118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sainz B Jr and Heeschen C: Standing out
from the crowd: Cancer stem cells in hepatocellular carcinoma.
Cancer Cell. 23:431–433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang B and Jacob ST: Role of cancer stem
cells in hepatocarcinogenesis. Genome Med. 3:112011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu W, Baxter JE, Wattam SL, Hayward DG,
Fardilha M, Knebel A, Ford EM, da Cruz e Silva EF and Fry AM:
Alternative splicing controls nuclear translocation of the cell
cycle-regulated Nek2 kinase. J Biol Chem. 282:26431–26440. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou W, Yang Y, Xia J, Wang H, Salama ME,
Xiong W, Xu H, Shetty S, Chen T, Zeng Z, et al: NEK2 induces drug
resistance mainly through activation of efflux drug pumps and is
associated with poor prognosis in myeloma and other cancers. Cancer
Cell. 23:48–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Neal CP, Fry AM, Moreman C, McGregor A,
Garcea G, Berry DP and Manson MM: Overexpression of the Nek2 kinase
in colorectal cancer correlates with beta-catenin relocalization
and shortened cancer-specific survival. J Surg Oncol. 110:828–838.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi Y, Iwaya T, Sawada G, Kurashige
J, Matsumura T, Uchi R, Ueo H, Takano Y, Eguchi H, Sudo T, et al:
Up-regulation of NEK2 by microRNA-128 methylation is associated
with poor prognosis in colorectal cancer. Ann Surg Oncol.
21:205–212. 2014. View Article : Google Scholar
|
|
10
|
Wang S, Li W, Lv S, Wang Y, Liu Z, Zhang
J, Liu T and Niu Y: Abnormal expression of Nek2 and β-catenin in
breast carcinoma: Clinicopathological correlations. Histopathology.
59:631–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marina M and Saavedra HI: Nek2 and Plk4:
Prognostic markers, drivers of breast tumorigenesis and drug
resistance. Front Biosci (Landmark Ed). 19:352–365. 2014.
View Article : Google Scholar
|
|
12
|
Zhong X, Guan X, Dong Q, Yang S, Liu W and
Zhang L: Examining Nek2 as a better proliferation marker in
non-small cell lung cancer prognosis. Tumour Biol. 35:7155–7162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bahmanyar S, Kaplan DD, Deluca JG,
Giddings TH Jr, O'Toole ET, Winey M, Salmon ED, Casey PJ, Nelson WJ
and Barth AI: beta-Catenin is a Nek2 substrate involved in
centrosome separation. Genes Dev. 22:91–105. 2008. View Article : Google Scholar :
|
|
14
|
Mbom BC, Siemers KA, Ostrowski MA, Nelson
WJ and Barth AI: Nek2 phosphorylates and stabilizes β-catenin at
mitotic centrosomes downstream of Plk1. Mol Biol Cell. 25:977–991.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen L, Yuan YF, Li Y, Chan TH, Zheng BJ,
Huang J and Guan XY: Clinical significance of CHD1L in
hepatocellular carcinoma and therapeutic potentials of
virus-mediated CHD1L depletion. Gut. 60:534–543. 2011. View Article : Google Scholar
|
|
16
|
Chen D, Xing W, Hong J, Wang M, Huang Y,
Zhu C, Yuan Y and Zeng W: The beta2-adrenergic receptor is a
potential prognostic biomarker for human hepatocellular carcinoma
after curative resection. Ann Surg Oncol. 19:3556–3565. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang S, Li W, Liu N, Zhang F, Liu H, Liu
F, Liu J, Zhang T and Niu Y: Nek2A contributes to tumorigenic
growth and possibly functions as potential therapeutic target for
human breast cancer. J Cell Biochem. 113:1904–1914. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wurmbach E, Chen YB, Khitrov G, Zhang W,
Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, et
al: Genome-wide molecular profiles of HCV-induced dysplasia and
hepatocellular carcinoma. Hepatology. 45:938–947. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roessler S, Jia HL, Budhu A, Forgues M, Ye
QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, et al: A
unique metastasis gene signature enables prediction of tumor
relapse in early-stage hepatocellular carcinoma patients. Cancer
Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dravid G, Ye Z, Hammond H, Chen G, Pyle A,
Donovan P, Yu X and Cheng L: Defining the role of Wnt/beta-catenin
signaling in the survival, proliferation, and self-renewal of human
embryonic stem cells. Stem Cells. 23:1489–1501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sato N, Meijer L, Skaltsounis L, Greengard
P and Brivanlou AH: Maintenance of pluripotency in human and mouse
embryonic stem cells through activation of Wnt signaling by a
pharmacological GSK-3-specific inhibitor. Nat Med. 10:55–63. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamashita T, Budhu A, Forgues M and Wang
XW: Activation of hepatic stem cell marker EpCAM by
Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res.
67:10831–10839. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu
LX, Zhang SH, Huang DD, Tang L, Kong XN, et al: Wnt/beta-catenin
signaling contributes to activation of normal and tumorigenic liver
progenitor cells. Cancer Res. 68:4287–4295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Monga SP: β-catenin signaling and roles in
liver homeostasis, injury, and tumorigenesis. Gastroenterology.
148:1294–1310. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pan W, Choi SC, Wang H, Qin Y,
Volpicelli-Daley L, Swan L, Lucast L, Khoo C, Zhang X, Li L, et al:
Wnt3a-mediated formation of phosphatidylinositol 4,5-bisphosphate
regulates LRP6 phosphorylation. Science. 321:1350–1353. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang KL, Han L, Chen LY, Shi ZD, Yang M,
Ren Y, Chen LC, Zhang JX, Pu PY and Kang CS: Blockage of a
miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in
glioblastomas. Cancer Lett. 342:139–149. 2014. View Article : Google Scholar
|
|
27
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cappello P, Blaser H, Gorrini C, Lin DC,
Elia AJ, Wakeham A, Haider S, Boutros PC, Mason JM, Miller NA, et
al: Role of Nek2 on centrosome duplication and aneuploidy in breast
cancer cells. Oncogene. 33:2375–2384. 2014. View Article : Google Scholar
|
|
29
|
Naro C, Barbagallo F, Chieffi P, Bourgeois
CF, Paronetto MP and Sette C: The centrosomal kinase NEK2 is a
novel splicing factor kinase involved in cell survival. Nucleic
Acids Res. 42:3218–3227. 2014. View Article : Google Scholar :
|
|
30
|
Pei D: Regulation of pluripotency and
reprogramming by transcription factors. J Biol Chem. 284:3365–3369.
2009. View Article : Google Scholar
|
|
31
|
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO,
Zheng BJ and Guan XY: Identification and characterization of
tumorigenic liver cancer stem/progenitor cells. Gastroenterology.
132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamashita T, Honda M, Nakamoto Y, Baba M,
Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, et al:
Discrete nature of EpCAM+ and CD90+ cancer
stem cells in human hepatocellular carcinoma. Hepatology.
57:1484–1497. 2013. View Article : Google Scholar
|
|
33
|
Kawai T, Yasuchika K, Ishii T, Katayama H,
Yoshitoshi EY, Ogiso S, Kita S, Yasuda K, Fukumitsu K, Mizumoto M,
et al: Keratin 19, a cancer stem cell marker in human
hepatocellular carcinoma. Clin Cancer Res. 21:3081–3091. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng YW, Nie YZ and Taniguchi H: Cellular
reprogramming and hepatocellular carcinoma development. World J
Gastroenterol. 19:8850–8860. 2013. View Article : Google Scholar :
|
|
35
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kanwar SS, Yu Y, Nautiyal J, Patel BB and
Majumdar AP: The Wnt/beta-catenin pathway regulates growth and
maintenance of colonospheres. Mol Cancer. 9:2122010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Terris B, Cavard C and Perret C: EpCAM, a
new marker for cancer stem cells in hepatocellular carcinoma. J
Hepatol. 52:280–281. 2010. View Article : Google Scholar
|
|
38
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hu X, Ghisolfi L, Keates AC, Zhang J,
Xiang S, Lee DK and Li CJ: Induction of cancer cell stemness by
chemotherapy. Cell Cycle. 11:2691–2698. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E,
Zhan X, Janz S, Tricot G and Zhan F: NEK2 mediates
ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget.
5:11986–11997. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Robey RW, To KK, Polgar O, Dohse M, Fetsch
P, Dean M and Bates SE: ABCG2: A perspective. Adv Drug Deliv Rev.
61:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang G, Wang Z, Luo W, Jiao H, Wu J and
Jiang C: Expression of potential cancer stem cell marker ABCG2 is
associated with malignant behaviors of hepatocellular carcinoma.
Gastroenterol Res Pract. 2013:7825812013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Koppaka V, Thompson DC, Chen Y, Ellermann
M, Nicolaou KC, Juvonen RO, Petersen D, Deitrich RA, Hurley TD and
Vasiliou V: Aldehyde dehydrogenase inhibitors: A comprehensive
review of the pharmacology, mechanism of action, substrate
specificity, and clinical application. Pharmacol Rev. 64:520–539.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Luo Y, Dallaglio K, Chen Y, Robinson WA,
Robinson SE, McCarter MD, Wang J, Gonzalez R, Thompson DC, Norris
DA, et al: ALDH1A isozymes are markers of human melanoma stem cells
and potential therapeutic targets. Stem Cells. 30:2100–2113. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Balicki D: Moving forward in human mammary
stem cell biology and breast cancer prognostication using ALDH1.
Cell Stem Cell. 1:485–487. 2007. View Article : Google Scholar
|
|
48
|
Choi SA, Lee JY, Phi JH, Wang KC, Park CK,
Park SH and Kim SK: Identification of brain tumour initiating cells
using the stem cell marker aldehyde dehydrogenase. Eur J Cancer.
50:137–149. 2014. View Article : Google Scholar
|
